YD Bio (YDES)

A core part of YD Bio’s business is linked to oncology diagnostics. The company is involved in DNA methylation-based cancer testing programmes in the United States under a laboratory developed test, or LDT, framework. These programmes are conducted with laboratory partners that are CLIA-certified and CAP-accredited, reflecting the regulated environment in which clinical laboratory testing is performed. DNA methylation analysis is an area of growing interest in cancer detection and monitoring because it examines epigenetic changes that may be associated with disease biology.

Beyond diagnostics, YD Bio provides life science distribution and clinical trial supply chain services. These activities can include procurement, logistics coordination, and compliance-focused support for organisations running clinical development programmes. Such services are important in biotechnology and pharmaceutical research, where timely delivery, documentation, and regulatory alignment can affect trial execution.

The company also maintains healthcare product commercialisation operations, including ocular health products in the United States and consumer healthcare distribution in Asia. This mix gives YD Bio exposure to both specialised clinical markets and broader healthcare product channels. For investors, the company’s profile is shaped by its ability to advance diagnostic programmes, maintain high-quality laboratory and distribution partnerships, and manage commercial execution across different regulatory and regional markets.